Somewhat Favorable Press Coverage Somewhat Unlikely to Impact CTI BioPharma (CTIC) Share Price
News headlines about CTI BioPharma (NASDAQ:CTIC) have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CTI BioPharma earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.618567357303 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of CTI BioPharma (NASDAQ CTIC) opened at $3.41 on Friday. The company has a current ratio of 2.19, a quick ratio of 2.17 and a debt-to-equity ratio of 0.26. CTI BioPharma has a twelve month low of $2.45 and a twelve month high of $5.64. The company has a market capitalization of $146.52, a PE ratio of -2.87 and a beta of 0.53.
CTI BioPharma (NASDAQ:CTIC) last released its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.04. The firm had revenue of $1.71 million during the quarter, compared to the consensus estimate of $0.30 million. CTI BioPharma had a negative return on equity of 209.67% and a negative net margin of 96.91%. analysts expect that CTI BioPharma will post -1.2 EPS for the current fiscal year.
A number of research firms recently commented on CTIC. Zacks Investment Research downgraded CTI BioPharma from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. ValuEngine downgraded CTI BioPharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 11th.
About CTI BioPharma
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.